Back to top
more

Clene (CLNN)

(Delayed Data from NSDQ)

$0.34 USD

0.34
314,817

0.00 (-0.68%)

Updated Apr 23, 2024 03:59 PM ET

After-Market: $0.34 0.00 (1.46%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of 14.29% and 21.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Dentsply International (XRAY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 2.33% and 4.50%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -83.33% and 0.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 25% and 21.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -11.11% and 0.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Karuna Therapeutics, Inc. (KRTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Karuna Therapeutics, Inc. (KRTX) delivered earnings and revenue surprises of 0.36% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Anavex Life Sciences (AVXL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Anavex Life Sciences (AVXL) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of 6.25% and 10.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 2.92% and 70.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.85% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Clene (CLNN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Clene Inc. (CLNN) and The Cooper Companies (COO) have performed compared to their sector so far this year.

Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of -6.67% and 73.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Celularity (CELU) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on updates on Celularity's (CELU) pipeline candidates when it reports its fourth-quarter earnings.

Clene Inc. (CLNN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of 39.13% and 228.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clene Inc. (CLNN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Clene Inc. (CLNN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of -4.76% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Clene Inc. (CLNN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of -16.67% and 76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 27.78% and 21.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

uniQure (QURE) Stock Jumps 8.1%: Will It Continue to Soar?

by Zacks Equity Research

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Clene Inc. (CLNN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Clene Inc. (CLNN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Clene Inc. (CLNN) Could Rally 288%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 287.8% upside potential for Clene Inc. (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.